On August 29th, 2023, the US Department of Health and Human Services (HHS) marked a pivotal turn in the war on drugs transition of marijuana from Schedule I to Schedule III.
The U.S. cannabis and hemp industry currently lacks comprehensive product characterization, primarily due to limited state testing regulations in this area and a lack of widespread implementation of current Good Manufacturing Practices (cGMP). While most states focus on testing a few active molecules, namely Δ9-THC, Δ9-THCA, CBD, and CBD-A, full identification of product components is generally not required.
In this episode, we delved into lab testing issues in the cannabis industry, including lab shopping and THC inflation. We highlighted the need for a new perspective on flower potency testing and the importance of representative sampling. We also discussed the misconceptions about THC content and quality, and the complexities of CRM shopping, measurement uncertainty, and shelf stability.
On August 29th, 2023, the US Department of Health and Human Services (HHS) marked a pivotal turn in the war on drugs transition of marijuana from Schedule I to Schedule III.
The U.S. cannabis and hemp industry currently lacks comprehensive product characterization, primarily due to limited state testing regulations in this area and a lack of widespread implementation of current Good Manufacturing Practices (cGMP). While most states focus on testing a few active molecules, namely Δ9-THC, Δ9-THCA, CBD, and CBD-A, full identification of product components is generally not required.
In this episode, we delved into lab testing issues in the cannabis industry, including lab shopping and THC inflation. We highlighted the need for a new perspective on flower potency testing and the importance of representative sampling. We also discussed the misconceptions about THC content and quality, and the complexities of CRM shopping, measurement uncertainty, and shelf stability.